AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 1,920,000 shares, an increase of 57.4% from the November 15th total of 1,220,000 shares. Based on an average trading volume of 321,500 shares, the short-interest ratio is currently 6.0 days.

AlloVir Trading Down 7.0 %

Shares of ALVR traded down $0.04 on Thursday, reaching $0.47. 315,019 shares of the company's stock traded hands, compared to its average volume of 599,134. The stock's 50 day simple moving average is $0.70 and its two-hundred day simple moving average is $0.74. The stock has a market cap of $54.30 million, a PE ratio of -0.57 and a beta of 0.59. AlloVir has a 52-week low of $0.45 and a 52-week high of $2.49.

AlloVir (NASDAQ:ALVR - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10.

Institutional Trading of AlloVir

Large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC raised its stake in shares of AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company's stock valued at $36,000 after buying an additional 30,072 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in AlloVir in the 2nd quarter valued at about $55,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in AlloVir by 127.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company's stock valued at $74,000 after purchasing an additional 54,900 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company's stock.

AlloVir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.